OS Therapies Engages Four Global Regulators In Q2 2026 Ahead Of Phase 3 Osteosarcoma Trial Enrollment Expected To Begin In Australia

OS Therapies is scheduled to meet with four global regulatory agencies in Q2 2026, ahead of the expected enrollment for a Phase 3 osteosarcoma trial in Australia, set to begin in Q3 2026. The Phase 3 study is necessary for the company to pursue a Biologics License Application (BLA) under the U.S. Accelerated Approval Program and Conditional Marketing Authorisations (CMAs) in the U.K. and Europe.